Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Non-Current Deffered Revenue (2021 - 2022)

Maxcyte (MXCT) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $344600.0 as the latest value for Q3 2022.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $344600.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $344600.0, a N/A change, with the full-year FY2021 number at $450200.0, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $344600.0 for Q3 2022 at Maxcyte, down from $450200.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $450200.0 in Q4 2021 to a low of $344600.0 in Q3 2022.